CERS · Cerus Corp · Webcasts, Transcripts & Audio
$1.99
+0.05 (+2.32%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$400.88M
Shares
201.95M
Volume · Nov 13
1.82M
Avg daily vol (3M)
1.94M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Cerus Corp Webcasts
Earnings calls, investor updates, investor days and conferences for Cerus Corp (CERS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-02
Cerus Corp (CERS) Q3 2026 Earnings Call Transcript
Positive tone
Phase 3 Redis clinical results
Revenue growth and financial progress
INT 200 international rollout
Revenue
$57.71M
▲ 9.5% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-30
Cerus Corp (CERS) Q2 2026 Earnings Call Transcript
Confident tone
U.S. ISB franchise growth
EMEA / international expansion
ISD / fibrinogen adoption
Revenue
$57.44M
▲ 9.5% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
Cerus Corp (CERS) Q1 2026 Earnings Call Transcript
Confident tone
IFC franchise momentum
Raised full-year 2026 guidance
Blood Centers of America agreement execution
Revenue
$53.66M
▲ 24.1% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
Cerus Corp (CERS) Q4 2025 Earnings Call Transcript
Confident tone
U.S. platelet franchise and BCA agreement
IFC (Intercept Fibrinogen Complex) demand
EMEA growth and Germany opportunity
Revenue
$85.42M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Cerus Corp (CERS) Q3 2025 Earnings Call Transcript
Confident tone
IFC (red blood cells) business and kit model transition
Path to positive non-GAAP adjusted EBITDA
International / EMEA expansion
Revenue
$52.70M
Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Cerus Corp (CERS) Q2 2025 Earnings Call Transcript
Confident tone
IFC (Fibrinogen Complex) Growth
INT200 Illuminator Launch
Red Blood Cell CE Mark Submission (Europe)
Revenue
$52.45M
Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Cerus Corp (CERS) Q1 2025 Earnings Call Transcript
Confident tone
US platelet and IFC franchise growth
INT200 next-generation illumination device
INTERCEPT red blood cell CE Mark submission
Revenue
$43.24M
Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Cerus Corp (CERS) Q4 2024 Earnings Call Transcript
Confident tone
2025 Revenue Guidance & Outlook
International Geographic Expansion
U.S. IFC (Fibrinogen Complex) Franchise
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Cerus Corp (CERS) Q3 2024 Earnings Call Transcript
Confident tone
INTERCEPT Fibrinogen Complex (IFC)
Operating Cash Flow and EBITDA Leverage
BARDA Contract and RBC Program
Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Cerus Corp (CERS) Q2 2024 Earnings Call Transcript
Confident tone
IFC (Interluekin/synthetic) franchise growth
Adjusted EBITDA breakeven target
International expansion (Canada, EMEA, Middle East, China)
Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Cerus Corp (CERS) Q1 2024 Earnings Call Transcript
Positive tone
INTERCEPT Fibrinogen Complex (IFC)
Cash Flow & Working Capital
ReCePI Phase III RBC Trial
Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-05
Cerus Corp (CERS) Q4 2023 Earnings Call Transcript
Confident tone
INTERCEPT Fibrinogen Complex (IFC) U.S. launch
INTERCEPT platelet franchise growth
First positive non-GAAP adjusted EBITDA
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Cerus Corp (CERS) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Cerus Corp (CERS) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Cerus Corp (CERS) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Cerus Corp (CERS) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Cerus Corp (CERS) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Cerus Corp (CERS) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Cerus Corp (CERS) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Cerus Corp (CERS) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Cerus Corp (CERS) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Cerus Corp (CERS) Q2 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Cerus Corp (CERS) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q3
2020-10-29
Cerus Corp (CERS) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Cerus Corp (CERS) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Cerus Corp (CERS) Q1 2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–26 of 26 webcasts
Key facts
CIK
1020214
CUSIP
157085101
13F (30d)
142 filings
121 filers
Visit website
Investor relations